Comparison of intrauterine transfusion techniques in hemolytic disease of the fetus and newborn

被引:0
|
作者
van't Oever, R. M. [1 ,2 ,3 ]
van Duijn, V. M. [1 ]
Slaghekke, F. [1 ]
Haak, M. C. [1 ]
de Winter, D. P. [2 ,3 ,4 ]
Lopriore, E. [4 ]
de Haas, M. [2 ,3 ,5 ]
Le Cessie, S. [6 ,7 ]
Verweij, E. J. T. [1 ]
机构
[1] Leiden Univ, Dept Obstet, Div Fetal therapy, Med Ctr, Leiden, Netherlands
[2] Sanquin Res, Translat Immunohematol, Amsterdam, Netherlands
[3] Amsterdam UMC, Landsteiner Lab, Amsterdam, Netherlands
[4] Leiden Univ, Willem Alexander Childrens Hosp, Dept Pediat, Div Neonatol,Med Ctr, Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Dept Hematol, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands
关键词
anemia; blood transfusion; erythroblastosis; fetal therapies; HDFN; intrauterine blood transfusion; RED-CELL ALLOIMMUNIZATION; FETAL; MANAGEMENT; HEMORRHAGE; ANEMIA;
D O I
10.1002/uog.29201
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Objectives: Intrauterine transfusions (IUTs) are the cornerstone in treatment for hemolytic disease of the fetus and newborn (HDFN). It has been suggested that a non-vascular intraperitoneal blood transfusion used in conjunction with an intravascular IUT can slow the decrease in fetal hemoglobin (Hb) levels, potentially extending the interval between transfusions. Our aim was to evaluate the rate of decline in Hb levels and the interval between transfusions using different IUT techniques, including intrahepatic transfusions with and without intraperitoneal transfusion, and transplacental transfusion at the site of the placental cord insertion. Methods: We conducted a retrospective cohort study at the Leiden University Medical Center, the national referral center for HDFN, between January 2006 and December 2022. All cases that underwent intrahepatic (with and without intraperitoneal transfusion) and placental cord insertion IUTs during the study period were included. The primary outcome was the decline in Hb levels per week, measured by comparing the Hb level immediately after the IUT with the Hb level before the subsequent IUT or birth. The primary outcome was analyzed using generalized estimating equations with and without adjustment for confounders. Results: We included 309 fetuses that received a total of 791 IUTs, of which 151 were intrahepatic-only transfusions, 273 were intrahepatic + intraperitoneal transfusions and 367 were placental cord insertion transfusions. We found an adjusted mean difference in the decline in Hb levels of 0.48 (95% CI, 0.29-0.66) g/dL/week between the group that underwent intrahepatic-only transfusion and the group that underwent intrahepatic + intraperitoneal transfusion (P < 0.001). The adjusted mean difference between the intrahepatic-only IUT group and the placental cord insertion IUT group was 0.49 (95% CI, 0.05-0.94) g/dL/week (P = 0.030). The median interval to the next IUT for the total cohort was 21 (interquartile range (IQR), 18-28) days. Similarly, in the intrahepatic-only and placental cord insertion IUT groups, the median interval to the next IUT was 21 (IQR, 19-28) and 21 (IQR, 15-26) days, respectively. In the intrahepatic + intraperitoneal transfusion group, the median interval was slightly higher (26 (IQR, 21-28) days). Conclusion: Decline in Hb levels was slower when using intrahepatic + intraperitoneal transfusion compared with other IUT techniques and seemed to prolong the interval between IUT procedures. The potential clinical advantages of the intrahepatic + intraperitoneal transfusion technique need to be weighed against the increased complexity and extended duration of the procedure on an individual basis. (c) 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Janssen's nipocalimab tackles hemolytic disease of the fetus and newborn
    Carvalho, Thiago
    NATURE MEDICINE, 2023, 29 (04) : 757 - 758
  • [42] Duration of hemolysis among infants with hemolytic disease of the fetus and newborn
    Bahr, Timothy M.
    Moise Jr, Kenneth J.
    Lowry, Kathy
    Monson, Martha A.
    Hammad, Ibrahim A.
    Goteti, Sasidhar
    Ilstrup, Sarah J.
    Vanasco, Paul
    Ohls, Robin K.
    Christensen, Robert D.
    JOURNAL OF PERINATOLOGY, 2025, 45 (02) : 268 - 270
  • [43] Hemolytic disease of the fetus and newborn caused by anti-Lan
    Brooks, Sarah
    Squires, Jerry E.
    TRANSFUSION, 2014, 54 (05) : 1317 - 1320
  • [44] Noninvasive approaches to the management of RhD hemolytic disease of the fetus and newborn
    Urbaniak, S. J.
    TRANSFUSION, 2008, 48 (01) : 2 - 5
  • [45] Antibody Titration in Hemolytic Disease of the Fetus and Newborn - State of the Art
    Flommersfeld, Sabine
    Ertl, Birgit
    TRANSFUSIONSMEDIZIN, 2018, 8 (02) : 90 - 94
  • [46] Variations and Opportunities in Postnatal Management of Hemolytic Disease of the Fetus and Newborn
    de Winter, Derek P.
    Verweij, E. J. T.
    Debeer, Anne
    Devlieger, Roland
    Lewi, Liesbeth
    Verbeeck, Sarah
    Maurice, Paul
    Jouannic, Jean-Marie
    Guillemin, Marie-Gabrielle
    Mailloux, Agnes
    dos Santos, Maria Cristina Pessoa
    Pacheco, Cynthia Amaral de Moura Sa
    Moreira, Maria Elisabeth Lopes
    Vaena, Marcella Martins de Vasconcelos
    Bohlin, Kajsa
    Tiblad, Eleonor
    Thorup, Emilie
    Petersen, Olav Bjorn
    Sanchez-Holgado, Maria
    Llorente, Aurora Viejo
    Poljak, Borna
    Khalil, Asma
    Le Duc, Kevin
    Ghesquiere, Louise
    Krivec, Jana Lozar
    Soltirovska-Salamon, Aneta
    Dame, Christof
    Blank, Jessica D.
    Hohnecker, Alexander
    Saxonhouse, Matthew
    Connors, Ngina K.
    Geipel, Annegret
    Rath, Johanna
    Prasad, Smriti
    van Wyk, Lizelle
    Geerts, Lut
    Schuler, Rahel
    Thon, Nina
    Leibovitch, Leah
    Cohen, Stav
    Canul-Euan, Arturo Alejandro
    Kelly, Edmond
    Raghuram, Kamini
    Cavigioli, Francesco
    Colombo, Sofia Fatima Guiseppina
    Elanjikal, Ziju
    Brayley, Jessica
    Pfurtscheller, Daniel
    Pichler, Gerhard
    Grisi, Angel Guillermo Alcazar
    JAMA NETWORK OPEN, 2025, 8 (01)
  • [47] Hemolytic Disease of the Fetus and Newborn due to Intravenous Drug Use
    Markham, Kara B.
    Scrape, Scott R.
    Prasad, Mona
    Rossi, Karen Q.
    O'Shaughnessy, Richard W.
    AJP REPORTS, 2016, 6 (01): : E129 - E132
  • [48] Hemolytic disease of the fetus and newborn due to multiple maternal antibodies
    Markham, Kara Beth
    Rossi, Karen Q.
    Nagaraja, Haikady N.
    O'Shaughnessy, Richard W.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 213 (01) : 68.e1 - 68.e5
  • [49] DURATION OF HEMOLYSIS AMONG INFANTS WITH HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN
    Bahr, T. M.
    Moise, K.
    Lowry, K.
    Monson, M.
    Hammad, I
    Goteti, S.
    Ilstrup, S. J.
    Vanasco, P.
    Ohls, R. K.
    Christensen, R. D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2025, 73 (01) : 527 - 528
  • [50] Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations
    Hendrickson, Jeanne E.
    Delaney, Meghan
    TRANSFUSION MEDICINE REVIEWS, 2016, 30 (04) : 159 - 164